IBM Watson Health announces slew of AI-based research partnership deals

IBM Watson Health today announced a number of new partnership deals, including an expanded collaborative deal with the Broad Institute of MIT and Harvard and 10-year, $50 million collaborative research deals with the Brigham and Women’s Hospital and the Vanderbilt University Medical Center. The Cambridge, Mass.-based IBM division said that it inked an extended partnership with the Broad Institute looking to analyze and explore genomics data to better understand the intrinsic possibility individuals have for a certain disease. The newly inked initiative aims to incorporate population-based and hospital-based biobank data, genomic information and electronic health records to improve and expand genetic risk scoring. The project plans to make its insights and tools widely available to the research community, including methods for calculating an individual’s risk of developing common diseases based on variants in the genome, IBM Watson said. “We’re excited to build upon the advances we’ve made in polygenic risk scoring utilizing vast amount of genomic data. By coupling clinical data with genomic data, there is an exceptional opportunity to make polygenic risk scoring more robust and powerful, and ultimately transformative for patient care. Such transformation could never happen without these kinds of partnerships,” Broad Institute cardiovascular disease initiative director Sekar Kathiresan said in a prepared statement. The deal expands upon a ...
Source: Mass Device - Category: Medical Devices Authors: Tags: Business/Financial News Featured Software / IT IBM Watson Health Source Type: news